Evinacumab

Excerpt

Evinacumab (evinacumab-dgnb) received approval from the United States Food and Drug Administration (FDA) in 2021 as an adjunct to other cholesterol-lowering treatments for patients aged 5 years and older diagnosed with homozygous familial hypercholesterolemia (HoFH). HoFH is a genetic disorder affecting lipid metabolism characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) levels of ≥300 mg/dL despite standard oral therapies due to diminished or absent LDL-receptor function. Early HoFH detection and prompt LDL-C level management are crucial to preventing hypercholesterolemia-related complications. Drug regimens in HoFH include a combination of lipid-lowering therapies such as statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These medications upregulate LDL-receptor expression in an attempt to reduce LDL-C levels.